Orexo AB (publ) (LON:0H19)

London flag London · Delayed Price · Currency is GBP · Price in SEK
28.50
-1.13 (-3.80%)
At close: Feb 11, 2026
Market Cap79.89M +66.2%
Revenue (ttm)2.10M -95.6%
Net Income51.53M
EPS1.49
Shares Outn/a
PE Ratio1.55
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume558
Average Volume260
Open29.30
Previous Close29.63
Day's Range28.50 - 28.85
52-Week Range12.90 - 41.20
Beta0.86
RSI42.45
Earnings DateFeb 5, 2026

About Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and ... [Read more]

Industry Pharmaceutical Preparations
Founded 1994
Employees 104
Stock Exchange London Stock Exchange
Ticker Symbol 0H19
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements